Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03141021 · ClinicalTrials.gov registry record

Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

A clinical trial of Malignant Peripheral Nerve Sheath Tumors, sponsored by Washington University School of Medicine.

Recruiting
Registry status
1,050
Enrollment target
13
Study locations

NCT03141021 is a study of Malignant Peripheral Nerve Sheath Tumors that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 1,050 participants, above the 460-participant average among 3 other Malignant Peripheral Nerve Sheath Tumors trials with a reported enrollment target (128% higher). The trial reports 13 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03141021, a study of Malignant Peripheral Nerve Sheath Tumors, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
1,050 participants
Enrollment target
13
Study locations

Study Summary

First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers. Although retrospective in nature, the resulting data from this registry may reveal previously unanticipated patterns, similar to the INFACT effort outcome. This registry would then allow the acquisition of data associated with MPNST biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing data for aggregate analyses). Second, the investigators plan to co-register patients to institutional banks in order to prospectively collect MPNST samples for analysis. These patients will be consented in order to collect the above information and for banking of tumor tissue and future studies that include genomic characterization of the tumors.

Study Locations (13)

Maryland

  • Johns Hopkins - Baltimore
  • National Institutes of Health (NIH) - Bethesda

Other

  • Global Gene Corporation - Mumbai
  • Royal National Orthopedic Hospital - London

Florida

  • Moffitt Cancer Center - Tampa

Massachusetts

  • Dana Farber Cancer Institute - Boston

Minnesota

  • University of Minnesota - Minneapolis

Missouri

  • Washington University School of Medicine - St Louis

New York

  • Memorial Sloan Kettering Cancer Center - New York

Rhode Island

  • Lifespan - Providence

Trial Details

FieldValue
Enrollment Target 1,050 participants
Start Date 2017-04-28
Est. Completion 2053-04-30

What the Registry Record Tells You About NCT03141021

The ClinicalTrials.gov registry entry for NCT03141021 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,050 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 460-participant average among 3 other Malignant Peripheral Nerve Sheath Tumors trials with a reported enrollment target (128% higher). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malignant Peripheral Nerve Sheath Tumors appearing as the primary indexed condition, and to 0 interventions.

NCT03141021 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Maryland, Other, Florida.

Frequently Asked Questions

What is clinical trial NCT03141021 about?

NCT03141021 is a clinical study titled "Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors". First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established,...

What is the current status of trial NCT03141021?

This trial is currently recruiting. The enrollment target is 1,050 participants. The study started on 2017-04-28. Estimated completion is 2053-04-30.

What conditions does trial NCT03141021 study?

This clinical trial studies the following conditions: Malignant Peripheral Nerve Sheath Tumors.

Who is sponsoring clinical trial NCT03141021?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03141021 being conducted?

This trial has 13 study locations across Florida, Maryland, Massachusetts, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Peripheral Nerve Sheath Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.